Skip to main content

Advertisement

SpringerLink
Log in

RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study

  • Letter to the Editor
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 16 March 2023

    “RE:” has been added in the article title to differentiate it from Original Article.

References

  1. Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, Kanamori N, Makuuchi M, Honda H (2022) One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int. https://doi.org/10.1007/s00223-022-01031-6

    Article  PubMed  PubMed Central  Google Scholar 

  2. Cejka D, Jäger-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M (2012) Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 27(1):226–230

    Article  CAS  PubMed  Google Scholar 

  3. De Maré A, Opdebeeck B, Neven E, D’Haese PC, Verhulst A (2022) Sclerostin protects against vascular calcification development in mice. J Bone Miner Res 37(4):687–699

    Article  PubMed  Google Scholar 

  4. Pazianas M (2019) Bones, heart and the new anabolic agent romosozumab. Postgrad Med J 95(1128):521–523

    Article  PubMed  Google Scholar 

  5. Brandenburg VM, Verhulst A, Babler A, D’Haese PC, Evenepoel P, Kaesler N (2019) Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephrol Dial Transplant 34(3):408–414

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funds, grants, or other support was received.

Author information

Authors and Affiliations

  1. Institute of Musculoskeletal Sciences, Oxford University, Oxford, OX3 7LD, UK

    Michael Pazianas

Authors
  1. Michael Pazianas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Pazianas.

Ethics declarations

Conflict of interest

Michael Pazianas has no conflicts of interest to declare that are relevant to the content of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pazianas, M. RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study. Calcif Tissue Int 112, 628–629 (2023). https://doi.org/10.1007/s00223-022-01055-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-022-01055-y

Search

Navigation